Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955831 | 1.00 | SLC18A3 (0.50) | SLC18A3FAAHCHRM4CHRM2CHRM5 | |
| SCHEMBL2955829 | 1.00 | SLC18A3 (0.50) | SLC18A3FAAHCHRM4CHRM2CHRM5 | |
| SCHEMBL2950391 | 0.97 | FAAH (0.50) | SLC18A3FAAHCHRM4CCR1 | |
| SCHEMBL2950390 | 0.97 | FAAH (0.50) | SLC18A3FAAHCHRM4CCR1 | |
| SCHEMBL2950387 | 0.97 | FAAH (0.50) | SLC18A3FAAHCHRM4CCR1 | |
| SCHEMBL2962880 | 0.83 | ALDH1A1 (0.64) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2956566 | 0.82 | ALDH1A1 (0.67) | CHRM4CCR1CYP2C9TSHR | |
| SCHEMBL2953459 | 0.80 | CCR1 (0.60) | FAAHCHRM4CCR1 | |
| SCHEMBL10723724 | 0.79 | CHRM4 (0.64) | FAAHCHRM4CYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL2950540 | 0.77 | CCR1 (0.61) | CHRM4CHRM2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | claimed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1866298-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105127-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | HSD17B1, HSD17B3, HSD17B2 | SLC18A3 1825/4885FAAH 734/4885CHRM4 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.